Melanotan 1 vs Melanotan 2: Compared - Dosage Peptide

Melanotan 1 vs Melanotan 2: Compared - Dosage Peptide Melanotan 1 (afamelanotide) is FDA-approved for EPP with human RCTs; Melanotan 2 is an unapproved gray-market tanning peptide. A research-use comparison. Search the tanning and peptide forums for “Melanotan 1 vs Melanotan 2” and you will find them treated as two flavors of the same product — one billed as the “milder” tan, the other as the “stronger” tan that also boosts libido. That framing is wrong in almost every way that matters. The two are different molecules, act on different receptors, were developed toward different goals, and sit on opposite ends of the evidence and regulatory spectrum. The single most important fact to state at the outset is this: no head-to-head study — human or animal — has ever compared Melanotan 1 against Melanotan 2. Every “comparison,” including this one, is cross-trial inference across separate molecules, endpoints, and settings.[1] The second fact reframes the whole pairing. A Melanotan-1 molecule — afamelanotide — is an FDA- and EMA-approved prescription drug, while Melanotan 2 has never been approved by any regulator, anywhere, for anything. Afamelanotide (brand name SCENESSE) is approved to reduce phototoxic pain in a rare inherited skin disease; Melanotan 2 circulates only as an unlicensed gray-market “research chemical,” and its published human record consists mostly of case reports documenting harm rather than proven benefit.[4] Untangling that asymmetry — without overstating either side — is the main job of this article. This is educational reference material that summarizes published research and regulatory status. It is not medical advice, not a therapeutic recommendation, and not instructions for human use. Melanotan 2 is not approved for cosmetic tanning, sexual function, or any other use, and any dosing figures cited below describe laboratory-research conventions and approved-label facts only — not a protocol you should follow. Both compounds are melanocortin peptides that can darken skin, which is why they are marketed together. But they are structurally different molecules with different receptor targets, different research contexts, and sharply different regulatory footprints. The table below is the orientation; every row is unpacked, with citations, in the sections that follow. What it is Synthetic linear tridecapeptide analog of α-melanocyte-stimulating hormone (α-MSH), i.e. [Nle4, D-Phe7]-α-MSH (NDP-α-MSH). Marketed as afamelanotide (SCENESSE) Synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) — a smaller, distinct molecule Receptor target MC1R-preferential melanocortin agonist; drives eumelanin synthesis largely independent of UV[2] Broad, non-selective agonist at MC1R, MC3R, MC4R and MC5R; the MC4R activity adds erectile/libido and appetite/nausea effects Main research / use context Photoprotection in erythropoietic protoporphyria (EPP) — an approved clinical indication[1] Cosmetic (“sunless”) tanning and sexual-desire effects; no approved indication Highest human evidence tier Human RCTs. Two multicenter, randomized, double-blind, placebo-controlled trials underpin its approval[1] Case reports / case series only. No efficacy RCT; published human data mostly document harm[4][5] Approval status Approved as afamelanotide: FDA (8 Oct 2019) and EMA (Dec 2014) for EPP in adults[3] Not approved by FDA, EMA, or any major regulator, for any indication. Unlicensed / research-use only Head-to-head data None — no study has ever compared the two directly Any ranking of the two is cross-trial inference, not a measured result Melanotan 1 is a synthetic linear tridecapeptide — a 13-amino-acid analog of the body’s own α-melanocyte-stimulating hormone (α-MSH). Its formal shorthand is [Nle4, D-Phe7]-α-MSH, often written NDP-α-MSH: two amino-acid substitutions make it far more stable and potent than native α-MSH while keeping the same receptor behavior. Developed into a pharmaceutical, it is known generically as afamelanotide and sold under the brand name SCENESSE. Mechanistically, afamelanotide is a melanocortin-1 receptor (MC1R)-preferential agonist. Binding MC1R on melanocytes drives the production of eumelanin — the dark, photoprotective form of the skin pigment melanin — and it does so largely independent of ultraviolet exposure, which is why it tans skin without sunlight.[2] That extra eumelanin is not merely cosmetic: in people with certain photosensitivity disorders it raises the skin’s tolerance to light. The approved use follows directly from this — reducing the phototoxic pain of erythropoietic protoporphyria, a rare inherited condition in which sunlight triggers severe skin pain. For the receptor-signaling background that these melanocortin analogs share, our reference on MC1R signaling in pigmentation research covers the pathway in depth. Melanotan 2 is a different molecule: a synthetic cyclic heptapeptide (7 amino acids, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2). The ring structure makes it smaller and more metabolically rugged than Melanotan 1, but the more consequential difference is receptor selectivity. Where Melanotan 1 prefers MC1R, Melanotan 2 is a broad, non-selective melanocortin agonist that also activates MC3R, MC4R and MC5R. The MC1R activity still drives pigmentation, but the added MC4R activity is what produces the erectile/libido effects and the appetite suppression and nausea that Melanotan 2 is notorious for — effects a MC1R-preferential molecule like Melanotan 1 does not share. Our explainer on how Melanotan 2 influences erectile mechanisms and the reference on Melanotan 2 in appetite-regulation research unpack that MC4R branch. The naming is genuinely confusing, and getting it wrong leads to real errors of interpretation. Three names sit close together in this space, and they are not interchangeable. The disambiguation table separates them. Melanotan 1 / afamelanotide / SCENESSE Linear tridecapeptide α-MSH analog (NDP-α-MSH); MC1R-preferential Approved drug (FDA 2019, EMA 2014) for EPP[3] Melanotan 2 (MT-II) Cyclic heptapeptide; broad MC1/3/4/5R agonist Not approved anywhere; gray-market research chemical Bremelanotide / PT-141 / Vyleesi A separate MC4R-focused molecule derived from Melanotan 2 — but not the same compound FDA-approved (2019) for HSDD — approval that does not transfer to Melanotan 2 That third row is the trap. Because bremelanotide (PT-141, marketed as Vyleesi) was engineered from Melanotan 2’s MC4R activity and did earn FDA approval for hypoactive sexual desire disorder, it is tempting to borrow that legitimacy for Melanotan 2 itself. That inference is invalid: bremelanotide is a distinct, purified, approved molecule; Melanotan 2 remains unapproved. The two must not be conflated. The compounds share one starting point: both are agonists at melanocortin receptors, and both can drive melanogenesis (pigment production) through MC1R. That shared MC1R action is why both darken skin, and it is the only place their pharmacology genuinely overlaps. For how MC1R activation translates into melanin output, see our reference on how Melanotan 2 influences melanin production. Below that shared node, the two diverge on selectivity, and selectivity is the whole story. Melanotan 1 (afamelanotide) is MC1R-preferential: it is comparatively focused on the pigmentation receptor, which is precisely why its clinically observed effects center on skin darkening and photoprotection rather than on sexual function or appetite.[2] Melanotan 2, by contrast, is a broad agonist that hits MC3R, MC4R and MC5R in addition to MC1R. The MC4R engagement recruits central pathways governing erectile response and satiety — the pharmacological reason Melanotan 2 both stiffens and nauseates, and the reason its MC4R-selective descendant became a sexual-function drug. In short: same pigment lever, but Melanotan 2 pulls several other levers at once, and those extra levers are where most of its risk lives. Both molecules trace back to melanocortin research aimed at a “tan without UV” as a way to reduce skin-cancer risk from sun exposure. From that program, two distinct peptides emerged — the linear MC1R-preferential analog that became afamelanotide, and the cyclic broad-spectrum analog that became Melanotan 2. Their paths then split completely. Afamelanotide was carried down the full pharmaceutical pathway: a defined molecule, a slow-release implant formulation, controlled clinical trials, and eventually orphan-drug approval for a rare disease.[3] Melanotan 2 never entered an approved development program; instead it moved into the online research-chemical and cosmetic-tanning market, where it is sold as lyophilized powder to be reconstituted and self-injected. That origin story explains the evidence gap: one compound accumulated regulated trial data, the other accumulated forum anecdotes and, in the medical literature, adverse-event case reports. Our overview of whether Melanotan 2 promotes sunless tanning — and the risks involved traces that gray-market trajectory. Stated plainly: a Melanotan-1 molecule is an approved drug; Melanotan 2 is not. Afamelanotide received EMA approval in December 2014 and FDA approval on 8 October 2019, in both cases specifically to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.[3][1] It is a marketed prescription product delivered by a healthcare professional. Two honest caveats sit on top of that approval. First, it is indication-specific: afamelanotide is approved for a rare photosensitivity disease, not for cosmetic tanning, and its approval says nothing about using a Melanotan-1 peptide to get a beach tan. Second, and more importantly for this comparison, the approval belongs to afamelanotide as a characterized implant — it does not extend to Melanotan 2 at all. Melanotan 2 has no marketing authorization from the FDA, the EMA, or any comparable regulator, and (as noted above) the FDA approval of the Melanotan-2-derived molecule bremelanotide/Vyleesi does not launder Melanotan 2 into an approved product. Afamelanotide’s distinguishing feature is that it has genuine randomized human trial data. Its approval rests on two multicenter, randomized, double-blind, placebo-controlled trials in patients with erythropoietic protoporphyria — one conducted in Europe and one in the United States — in which the afamelanotide implant increased the amount of pain-free time patients could spend in sunlight and was generally well tolerated, with adverse events that were mostly mild.[1] That is a real, high-tier evidence base for a specific disease endpoint, and it is why the drug reached the market. The supporting literature fills in the pharmacology. Clinical-pharmacology reviews describe how the MC1R-preferential mechanism translates into a measurable rise in melanin density and photoprotection, and how the slow-release implant delivers the peptide over weeks rather than as a short injectable pulse.[2] Because afamelanotide is an orphan drug, its broader potential in other pigmentary and photodermatologic conditions has also been reviewed, but those additional uses remain investigational rather than approved.[3] The honest summary: strong evidence for one narrow, approved indication; promising-but-unproven everywhere else. Melanotan 2’s human evidence base is the mirror image — and it is sobering. There is no efficacy randomized controlled trial demonstrating that Melanotan 2 safely and effectively tans skin or improves any health outcome. What exists in the peer-reviewed literature is a collection of case reports and small case series, and the majority of them describe harms rather than benefits. Dermatologists have documented the darkening and rapid change of existing moles, the eruption of new melanocytic nevi, and multiple instances of melanoma or melanoma in situ arising in people using Melanotan 2 — with the important caveat that a temporal association in a case report does not establish that the drug caused the cancer.[4][5] That signal is biologically coherent with the drug class. Melanocortin agonism stimulates melanocytes, and a related report describes eruptive nevi — a sudden crop of new moles — associated with an α-MSH analog, exactly the kind of pigment-cell proliferation one would predict from over-stimulating this pathway.[6] Beyond pigmentary effects, the gray-market literature also describes nausea and facial flushing, spontaneous penile erection (priapism, an MC4R-mediated effect), and occasional systemic reactions such as rhabdomyolysis. None of this is efficacy data; it is a safety-signal literature attached to an unregulated product of unverified content. Our reference on what the scientific evidence actually says about Melanotan 2 and skin disease reviews this record in more detail. This is the section that keeps the rest honest. No study has ever administered Melanotan 1 and Melanotan 2 to comparable subjects and measured them against each other. They were developed for different endpoints — medical photoprotection versus cosmetic tanning and sexual function — so a claim that one “tans better” or is “safer” than the other is stitched together from unrelated studies. Cross-trial inference can frame a hypothesis; it cannot rank the two. The table below grades each available line of evidence by the strength of its underlying design. Melanotan 1 (afamelanotide) increases pain-free light exposure in EPP Two multicenter randomized, double-blind, placebo-controlled trials[1] Well supported for that specific disease and endpoint; the basis of its approval Melanotan 1 for broader pigmentary / photodermatologic uses Narrative reviews of an orphan drug[3] Investigational; not approved for these uses Melanotan 2 tans skin safely and effectively No efficacy RCT; anecdote only Not established; unproven and unlicensed Melanotan 2 causes melanocytic-nevus change / melanoma Case reports / case series[4][5] A genuine safety signal; causality not established, monitoring advised Melanotan 1 “beats” Melanotan 2 (or vice versa) No head-to-head trial Cannot be claimed from evidence; cross-trial only Notice the pattern: the only high-tier, well-designed evidence in the entire pair belongs to Melanotan 1 for a rare disease — not to the cosmetic-tanning use that drives most searches, and not to Melanotan 2 at all. With the evidence framed, here is the detailed side-by-side. Two rows — half-life and dosing — carry a heavy caveat for Melanotan 2: no regulatory-grade human pharmacokinetic study characterizes it, so any circulating half-life figure is a research-use estimate, not an established value. The approved Melanotan-1 product, by contrast, has a defined label. Peptide class Linear tridecapeptide (13 aa) Cyclic heptapeptide (7 aa) Sequence identity [Nle4, D-Phe7]-α-MSH (NDP-α-MSH) Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 Receptor selectivity MC1R-preferential[2] Broad: MC1R, MC3R, MC4R, MC5R Route Subcutaneous slow-release implant (16 mg), placed by a healthcare professional above the anterior supra-iliac crest Subcutaneous injection of reconstituted gray-market powder; no standardized or sterile-verified route Half-life / duration Free peptide is short-lived, but the implant delivers drug over roughly two months, hence dosing every 60 days[2] Not characterized in humans by any regulatory-grade PK study; free peptide reported short (order of minutes to a few hours) — treat as research-use Dosing convention Clinical (label): one 16 mg implant every 2 months, administered by a clinician No approved dose. Gray-market injection dosing exists but is unlicensed and non-standardized Highest human evidence Randomized controlled trials[1] Case reports / case series only[5] FDA 2019 / EMA 2014 (afamelanotide, EPP)[3] Not approved anywhere The figures below are reported to help interpret the literature and the approved label. They are not a protocol for human use, and Melanotan 2 has no validated human dose for any purpose. Melanotan 1 (afamelanotide) — the approved clinical regimen is a single 16 mg subcutaneous implant every two months, placed by a healthcare professional; this is a prescription procedure, not a self-administered injection.[2] On dosagepeptide.com the research-grade free peptide is framed research-use-only — see the Melanotan 1 10 mg vial research dosage reference. Melanotan 2 — there is no approved clinical dose; gray-market “loading then maintenance” injection conventions circulate online but are unlicensed, non-standardized, and unsupported by trial data. See the Melanotan 2 10 mg vial research dosage reference, framed strictly for laboratory research. Anyone converting these figures into vial concentrations should treat them purely as laboratory reference points; our peptide reconstitution guide and dosage calculator explain the arithmetic without implying any human protocol. Safety is where the two compounds are most often flattened into a single “peptides are safe” claim, and the accurate picture is very different for each. One was studied in controlled trials with defined adverse-event reporting; the other is known mainly through harm reports attached to an unregulated product. Reported adverse effects Mostly mild in the pivotal RCTs: nausea, headache, implant-site reactions, fatigue, and skin/nevus hyperpigmentation[1] Nausea and flushing; priapism (MC4R-mediated); darkening and proliferation of moles; case reports of melanoma temporally associated with use[4] Melanocyte / nevus monitoring Advised — the drug is pro-melanogenic, so periodic full-body skin and mole checks are recommended even for the approved product[2] Strongly emphasized — new/changing moles and melanoma signals are the central documented concern[5][6] Depth of human safety data Controlled-trial adverse-event data; serious events not attributed to the drug[1] Case-level only; no systematic safety dataset Product-identity risk Low — a characterized, manufactured pharmaceutical implant High — unregulated powder of unverified identity, purity, and sterility Mapping each compound to its actual research context prevents the most common error — treating them as interchangeable tanning agents. The table below pairs each research area with the real evidence each compound carries in it. Photoprotection in EPP Randomized controlled trials; approved use[1] No data Human RCT (Melanotan 1) Cosmetic / sunless tanning Not an approved use; pigmentation mechanism characterized[2] Anecdote + harm case reports; no efficacy RCT[4] Neither is proven for cosmetic use Sexual function (erectile / libido) Not applicable (MC1R-preferential) MC4R-driven effects reported; unproven and unapproved Neither — see bremelanotide (a separate drug) Appetite / metabolic effects Not applicable MC4R-driven appetite effects explored in research models Preclinical / exploratory only Melanocyte / nevus safety Monitoring advised (pro-melanogenic)[2] Melanoma / nevus case reports[5] Case-level safety signal For the receptor-level detail behind these rows, our references on how Melanotan 2 affects MC1 receptor activity in skin-pigmentation research add the mechanistic context that the case-report literature lacks. Being explicit about the gaps is part of reading this pair honestly. The published record does not show any of the following: That Melanotan 1 or Melanotan 2 is superior to the other — no head-to-head trial exists. That Melanotan 2 is a safe or effective way to tan — there is no efficacy RCT, only anecdote and adverse-event reports. That the FDA/EMA approval of afamelanotide extends to cosmetic tanning, or to Melanotan 2 in any form — it does not. That the approval of bremelanotide/Vyleesi makes Melanotan 2 approved — bremelanotide is a separate molecule. That Melanotan 2 causes melanoma — the case reports are a temporal signal, not proof of causation; equally, they cannot be dismissed as coincidence. That any circulating Melanotan-2 half-life or dose figure is validated human pharmacokinetics — none has been established by a regulatory-grade study. Several structural limitations constrain everything above, and honest readers should keep them in view: No head-to-head data. Comparing the two requires stitching together unrelated studies of different molecules, endpoints, and settings — a chain with several weak links. Asymmetric literature. One compound has controlled trials; the other has case reports. That is not a like-for-like evidence comparison, and the asymmetry itself is the finding. Approved drug ≠ research powder. Afamelanotide’s trial data describe a characterized implant delivered by clinicians — not a self-injected research vial of a Melanotan-1 peptide, and certainly not Melanotan 2. Case-report bias. Harm reports document what was noticed and published; they cannot establish incidence, causation, or safe use. Research-chemical identity. Gray-market Melanotan 2 is of unverified identity, purity, and sterility; trial or label data never describe what is actually in such a vial. For readers using this material to interpret the literature rather than to guide any human use, a few practical anchors help. The vocabulary in this article — melanocortin receptor, eumelanin, MC1R, MC4R, tridecapeptide, cyclic peptide — is defined in our peptide research glossary, and the laboratory arithmetic of reconstitution and concentration is covered in the reconstitution guide and dosage calculator. None of these is a recommendation for human administration; they describe how these compounds are characterized in research. Because gray-market Melanotan 2 in particular is sold outside any approved supply chain, its identity and purity are unverified — and identity confirmation (for example by mass spectrometry and HPLC, with a batch certificate of analysis) is the minimum characterization a rigorous research setting would require before drawing any conclusion. Reference vials of these melanocortin peptides are catalogued by research-grade suppliers such as Prime Lab Peptides. Sourcing a tested material does not change the evidence picture described above: the approval and trial data belong to afamelanotide as a clinical product, they do not transfer to any research vial or to Melanotan 2, and nothing here is a therapeutic recommendation or a protocol for use. They are not. Melanotan 1 (afamelanotide) is a linear 13-amino-acid α-MSH analog that is MC1R-preferential; Melanotan 2 is a smaller cyclic 7-amino-acid peptide that activates MC1R, MC3R, MC4R and MC5R. The extra receptor activity is why Melanotan 2 has erectile and appetite effects that Melanotan 1 does not, and why their safety profiles differ. Only afamelanotide (a Melanotan-1 molecule) is approved, and only to reduce phototoxic pain in erythropoietic protoporphyria — not for cosmetic tanning. Melanotan 2 is not approved anywhere. An approval for one molecule and one rare disease does not make a different, unapproved molecule safe for a cosmetic use. No. Bremelanotide (PT-141, Vyleesi) is a separate, purified MC4R-focused molecule derived from Melanotan 2, approved for hypoactive sexual desire disorder. Melanotan 2 itself has never been approved. Approval does not transfer between related-but-distinct molecules. The honest statement is more careful: multiple case reports describe melanoma and changing moles temporally associated with Melanotan 2 use, which is a genuine safety signal that warrants melanocyte monitoring. But case reports cannot establish causation, so “definitely causes” overstates the evidence just as “totally safe” ignores it. Different molecules. Melanotan 1 is a linear MC1R-preferential α-MSH analog (afamelanotide); Melanotan 2 is a smaller cyclic broad-spectrum melanocortin agonist. Sharp approval asymmetry. Afamelanotide is FDA- (2019) and EMA-approved (2014) for EPP; Melanotan 2 is not approved by any regulator for anything. Asymmetric evidence. Melanotan 1 has human randomized trials; Melanotan 2’s human literature is case reports, mostly of harm. No head-to-head trial exists — every direct ranking of the two is cross-trial inference. Melanotan 2 carries specific safety signals — nausea, priapism, and darkening/proliferation of moles with melanoma case reports; melanocyte monitoring is advised. Even the approved Melanotan-1 drug, being pro-melanogenic, warrants skin checks. Research-use only. Gray-market material has unverified identity and purity; trial and label data are not product data, and nothing here is medical advice or a protocol for use. Melanotan 1 is a linear 13-amino-acid analog of α-MSH (afamelanotide) that mainly activates the MC1R pigmentation receptor. Melanotan 2 is a smaller cyclic 7-amino-acid peptide that activates MC1R plus MC3R, MC4R and MC5R. The broader receptor activity gives Melanotan 2 additional erectile, libido and appetite effects, and a different, more concerning safety profile. A Melanotan-1 molecule is: afamelanotide (SCENESSE) was FDA-approved on 8 October 2019 and EMA-approved in December 2014 to reduce phototoxic pain in adults with erythropoietic protoporphyria. Melanotan 2 has never been approved by the FDA, EMA, or any major regulator for any indication. Yes. “Melanotan 1” is the research name for the α-MSH analog developed into the drug afamelanotide, which is marketed under the brand name SCENESSE. It is delivered as a subcutaneous slow-release implant placed by a healthcare professional, not as a self-administered injection. No. There is no study — human or animal — that compares Melanotan 1 and Melanotan 2 directly. They were developed toward different endpoints, so any claim that one is better, stronger, or safer than the other is cross-trial inference across unrelated studies, not a measured result. The difference is receptor selectivity. Melanotan 2 activates MC4R in addition to MC1R, and MC4R signaling drives erectile response, libido and satiety. Melanotan 1 (afamelanotide) is MC1R-preferential, so it centers on skin pigmentation and photoprotection without the same MC4R-mediated sexual and appetite effects. The published literature contains multiple case reports of melanoma and changing moles temporally associated with Melanotan 2 use, which is a real safety signal and a reason melanocyte monitoring is advised. However, case reports cannot prove causation, so it is accurate to describe an association that warrants caution rather than a proven cause.